<DOC>
	<DOCNO>NCT00469144</DOCNO>
	<brief_summary>The goal clinical research study learn give busulfan dose base blood level , along fix ( unchanging ) dose fludarabine , effective cause few side effect AML myelodysplastic syndrome patient standard method give fix busulfan dose base body size , along fix dose fludarabine . The safety dose base blood level also study .</brief_summary>
	<brief_title>IV Busulfan With Allo-BMT : Study Patients With Acute Myelogenous Leukemia Myelodysplastic Syndrome</brief_title>
	<detailed_description>Busulfan chemotherapy drug kill cancer cell bind DNA , commonly used stem cell transplantation . Fludarabine antimetabolite drug anti-leukemia immunosuppressive effect . If eligible take part study , randomly assign ( toss coin ) 1 2 study group . One group receive fix dose busulfan , group receive adjust dose busulfan base blood level drug . Both group receive fludarabine treatment well stem cell transplant . Patients adjusted-dose group first receive low-level `` test '' dose busulfan check blood level change time ; information use decide next dose need reach target blood level match body size . Patients fixed-dose group receive fix dose busulfan without test dose . If assign fixed-dose group , measurement affect dose level unusually high low drug level blood . Patients group total 20 teaspoon ( less 7 tablespoon ) blood drawn time check busulfan blood level follow one busulfan treatment . About 11 sample blood drawn check blood level busulfan time follow test dose first high-dose busulfan treatment ; sample 1 teaspoon blood . A heparin lock place vein low number needle stick need draws . If possible blood level test perform technical scheduling reason , receive standard fix dose . Both group patient receive fludarabine central venous catheter ( CVC -- small tube insert one major vein , usually chest shoulder blade ) 1 hour , day , 4 day . After dose fludarabine , high-dose Busulfan infuse CVC 3 hour . These drug give try kill malignant cell suppress immune system order reduce risk stem cell transplant rejection . If go receive transplant HLA-type-nonidentical unrelated donor , also receive Thymoglobulin ( ATG ) 4 hour 3 day prior transplant suppress immune system . After 2 day rest , allogeneic stem cell ( bone marrow peripheral blood stem cell ) give intravenously ( IV -- needle vein ) . You receive drug G-CSF ( Neupogen ) injection skin daily start 1 week transplant blood cell level return normal . Patients usually remain hospital 4 week stem cell transplantation . After release hospital , continue outpatient hospital area monitor infection transplant-related complication minimum 100 day transplant . Patients previously leukemia involvement nervous system may need receive spinal tap , injection cytosine arabinoside hydrocortisone , several time year transplantation try keep leukemia come back . You undergo blood test bone marrow biopsy 3 , 6 , 12 month transplant , check disease remission . Your health status follow along local physician find leukemia myelodysplastic syndrome come back , well check length survival . This investigational study . All drug use study approve FDA treatment cancer . Up 230 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>1 . Acute myeloid leukemia past first remission , first subsequent relapse , first remission ( cytogenetics ( 8 ; 21 , inv 16 , ( 15 ; 17 ) ) induction failure . Only myeloid leukemia biphenotypic leukemia allow study . 2 . Myelodysplastic syndrome intermediate high risk International Prognostic Scoring System score 3 . Patient administer systemic chemotherapeutic drug ( include Mylotarg ) within 21 day prior trial enrollment ( BMT Day 7 day 9 testdose arm study ) . Hydroxyurea permit indicated control induction refractory disease , IT chemotherapy allow indicated maintenance treatment previously diagnose leptomeningeal disease , remission least 3 month prior enrollment study ) . 4 . No active infection . Protocol PI final arbiter uncertainty regard whether previous infection resolve . 5. age &lt; =65 6 . Patients must match related unrelated donor willing donate . A donor HLA identical mismatch 1 locus Class I [ HLA , A B ] , molecularly mismatch 1 locus Class II [ HLA , DR DQ ] also acceptable . 7 . ZUBROD performance status &lt; 2 8 . Life expectancy severely limited concomitant illness expect &gt; 12 week . 9 . Left ventricular ejection fraction &gt; 45 % No uncontrolled arrhythmias symptomatic cardiac disease . 10 . No symptomatic pulmonary disease . Forced expiratory volume one second ( FEV1 ) , force vital capacity ( FVC ) diffusion capacity lung carbon monoxide ( DLCO ) &gt; /= 50 % expect corrected hemoglobin . In patient &lt; /= 7 year pulmonary function assess per pediatric BMT routine 11 . Serum creatinine &lt; /= 1.5 mg % . 12 . Serum glutamate pyruvate transaminase ( SGPT ) &lt; /= 200 IU/ml , serum bilirubin alkaline phosphatase within accepted laboratory standard normal limit consider clinically significant . No evidence chronic active hepatitis cirrhosis . If positive hepatitis serology , discus Study Chairman consider liver biopsy . 13 . No effusion ascites &gt; 1L prior drainage . 14 . HIVnegative . 15 . Female patient pregnant ( negative Bhuman chorionic gonadotropin ( HCG ) pregnancy test woman childbearingpotential accordance departmental routine ) . 16 . Patient patient 's legal representative , parent ( ) guardian able sign inform consent . 17 . No prior autologous stem cell transplant 1 ) None .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Stem Cell Transplantation</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Busulfan</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>MDS</keyword>
	<keyword>AML</keyword>
</DOC>